Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Tanabe Research Laboratories (TRL), subsidiary of Mitsubishi Tanabe Pharma, has partnered with Anaphore for the research and preclinical development of novel protein therapies for autoimmune diseases based on Anaphore's proprietary Atrimer technology.
Subscribe to our email newsletter
Under the agreement, TRL and Anaphore will generate novel trivalent proteins called Atrimers that can be programmed to bind to and activate or inhibit targets of interest.
The partnership will focus on strategies to develop biologic therapies for autoimmune disorders such as, rheumatoid arthritis, inflammatory bowel disease, and psoriasis.
TRL and Anaphore will commence the research and development alliance immediately.
TRL chief scientific officer Roland Newman said that this collaboration with Anaphore will allow TRL to consolidate its position in autoimmune disease research and allow us to bring a new generation of biologics to physicians and their patients.